Trial Profile
A study of metabolomic profiling of response to Bevacizumab in the treatment of non-small cell lung cancer.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics
- 29 May 2014 New trial record